These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease. Nishikori A; Nishimura MF; Nishimura Y; Otsuka F; Maehama K; Ohsawa K; Momose S; Nakamura N; Sato Y Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142213 [TBL] [Abstract][Full Text] [Related]
45. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review. Leurs A; Gnemmi V; Lionet A; Renaud L; Gibier JB; Copin MC; Hachulla E; Hatron PY; Launay D; Fajgenbaum D; Terriou L Front Immunol; 2019; 10():1489. PubMed ID: 31316523 [No Abstract] [Full Text] [Related]
46. Bilateral Adrenal Infarctions as an Initial Manifestation of TAFRO Syndrome: A Case Report and Review of the Literature. Yonezaki S; Nagasaki K; Yamaguchi H; Kobayashi H Intern Med; 2022 Mar; 61(5):743-747. PubMed ID: 34393171 [TBL] [Abstract][Full Text] [Related]
47. Epstein-Barr Virus-Positive Cutaneous and Systemic Plasmacytosis with TAFRO Syndrome-like Symptoms Successfully Treated with Rituximab. Kakiuchi S; Akiyama H; Harima I; Takagi I; Rikitake J; Kozuki Y; Inaba M; Fujiwara H; Kurose N; Yamada S; Masaki Y Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837418 [TBL] [Abstract][Full Text] [Related]
48. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study. Zhang Y; Suo SS; Yang HJ; Zhou XP; You LS; Yu WJ; Wang ZM; Jin J J Cancer Res Clin Oncol; 2020 Feb; 146(2):357-365. PubMed ID: 31938902 [TBL] [Abstract][Full Text] [Related]
49. Japanese variant of multicentric castleman's disease associated with serositis and thrombocytopenia--a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? Masaki Y; Nakajima A; Iwao H; Kurose N; Sato T; Nakamura T; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Fukushima T; Okazaki T; Umehara H J Clin Exp Hematop; 2013; 53(1):79-85. PubMed ID: 23801138 [TBL] [Abstract][Full Text] [Related]
50. Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease. Bustamante MS; Pierson SK; Ren Y; Bagg A; Brandstadter JD; Srkalovic G; Mango N; Alapat D; Lechowicz MJ; Li H; Van Rhee F; Lim MS; Fajgenbaum DC Haematologica; 2024 Jul; 109(7):2196-2206. PubMed ID: 38205523 [TBL] [Abstract][Full Text] [Related]
51. TAFRO syndrome: A severe manifestation of Sjogren's syndrome? A systematic review. Grange L; Chalayer E; Boutboul D; Paul S; Galicier L; Gramont B; Killian M Autoimmun Rev; 2022 Aug; 21(8):103137. PubMed ID: 35803499 [TBL] [Abstract][Full Text] [Related]
52. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Fajgenbaum DC Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327 [TBL] [Abstract][Full Text] [Related]
53. FDG PET/CT Findings in TAFRO Syndrome. Hotta M; Minamimoto R; Yashima A; Nakano M; Yamashita H Clin Nucl Med; 2018 Nov; 43(11):828-829. PubMed ID: 30222681 [TBL] [Abstract][Full Text] [Related]
54. [TAFRO syndrome and monoclonal gammapathy: Uncommon association!]. Naifar M; Messedi M; Elleuch A; Snoussi M; Gouiaa N; Turki M; Lahiani A; Boudawara T; Bahloul Z; Ayedi F Curr Res Transl Med; 2016; 64(1):43-7. PubMed ID: 27140598 [TBL] [Abstract][Full Text] [Related]
55. Idiopathic multicentric Castleman disease-TAFRO after COVID-19: A case report. Shiina T; Yamamoto EK; Yamada H; Sendo S; Kanzawa M; Saegusa J Mod Rheumatol Case Rep; 2024 Aug; ():. PubMed ID: 39177383 [TBL] [Abstract][Full Text] [Related]
56. Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2. Konishi Y; Takahashi S; Nishi K; Sakamaki T; Mitani S; Kaneko H; Mizutani C; Ukyo N; Hirata H; Tsudo M Tohoku J Exp Med; 2015 Aug; 236(4):289-95. PubMed ID: 26250536 [TBL] [Abstract][Full Text] [Related]
57. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Fajgenbaum DC Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129 [TBL] [Abstract][Full Text] [Related]
58. Castleman disease and TAFRO syndrome. Masaki Y; Arita K; Sakai T; Takai K; Aoki S; Kawabata H Ann Hematol; 2022 Mar; 101(3):485-490. PubMed ID: 35044513 [TBL] [Abstract][Full Text] [Related]